Zacks.com on MSN1h
Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/YUltragenyx Pharmaceutical RARE reported fourth-quarter 2024 loss of $1.39 per share, wider than the Zacks Consensus Estimate ...
ALNY reports better-than-expected fourth-quarter results as both earnings and revenues beat estimates driven by higher ...
Alnylam Pharmaceuticals exceeded Wall Street's expectations with strong revenue growth and significant commercial progress.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback